Sibal Latika, Law Huong Nai, Gebbie Janice, Dashora Umesh K, Agarwal Sharad C, Home Philip
Newcastle Diabetes Centre, Newcastle upon Tyne, NE4 6BE, United Kingdom.
Ann N Y Acad Sci. 2006 Nov;1084:191-207. doi: 10.1196/annals.1372.037.
The aim of the article was to use prospectively collected data on people with type 1 diabetes to assess which routinely collected clinical measures predict the development of macrovascular disease in people with type 1 diabetes. Data have been collected in a structured format at an annual review since 1985. For this study, all people with type 1 diabetes in the database in both 1992 and 2001 were ascertained. Data were extracted for a diagnosis of coronary artery disease, stroke, and peripheral vascular disease (macrovascular complications). Presence of other microvascular complications was also ascertained. Forty-one of 404 (10.1%) people had macrovascular disease at the index visit in 1992 and 61 others developed macrovascular complications during follow-up. People who developed macrovascular complications were older (48 +/- 12 versus 36 +/- 11 [SD] years; P = 0.000), had longer duration of diabetes (28 +/- 12 versus 18 +/- 11 years; P = 0.000), higher BMI (26.7 +/- 4.6 versus 25.4 +/- 3.6 kg/m2; P = 0.041), higher base line serum cholesterol (5.9 +/- 1.7 versus 5.2 +/- 1.1 mmol/L, P = 0.007), higher median base line triglyceride levels (1.5 [IQ range 0.9-2.6] versus 1.1 [0.8-1.7] mmol/L; P = 0.002), higher systolic BP (145 +/- 21 versus 129 +/- 20 mmHg; P = 0.000), and higher serum creatinine (102 +/- 57 versus 86 +/- 17 micromol/L; P = 0.038) than those who did not. We found no significant difference in the base line glycated hemoglobin in the two groups. The multivariate model showed that age, duration of diabetes, systolic BP, and serum cholesterol and creatinine levels predicted the development of macrovascular complications, which were also associated with the later development of microalbuminuria. Macrovascular complications developed in 16.8% of people with type 1 diabetes over a 9-year follow-up, and were predicted by potentially modifiable factors including higher BP, BMI, and serum triglyceride and cholesterol levels.
本文的目的是利用前瞻性收集的1型糖尿病患者的数据,评估哪些常规收集的临床指标可预测1型糖尿病患者大血管疾病的发生。自1985年起,数据以结构化格式在年度复查时收集。对于本研究,确定了数据库中1992年和2001年的所有1型糖尿病患者。提取了冠状动脉疾病、中风和外周血管疾病(大血管并发症)的诊断数据。还确定了是否存在其他微血管并发症。在1992年的首次就诊时,404人中有41人(10.1%)患有大血管疾病,另外61人在随访期间出现了大血管并发症。出现大血管并发症的患者年龄更大(48±12岁对36±11岁[标准差];P = 0.000),糖尿病病程更长(28±12年对18±11年;P = 0.000),BMI更高(26.7±4.6对25.4±3.6 kg/m2;P = 0.041),基线血清胆固醇更高(5.9±1.7对5.2±1.1 mmol/L,P = 0.007),基线甘油三酯中位数水平更高(1.5[四分位间距0.9 - 2.6]对1.1[0.8 - 1.7] mmol/L;P = 0.002),收缩压更高(145±21对129±20 mmHg;P = 0.000),血清肌酐更高(102±57对86±17 μmol/L;P = 0.038)。我们发现两组的基线糖化血红蛋白无显著差异。多变量模型显示,年龄、糖尿病病程、收缩压以及血清胆固醇和肌酐水平可预测大血管并发症的发生,这些因素也与微量白蛋白尿的后期发生相关。在9年的随访中,16.8%的1型糖尿病患者出现了大血管并发症,可通过包括更高的血压、BMI以及血清甘油三酯和胆固醇水平等潜在可改变因素进行预测。